Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Protea Receives US Patent For New Protein Separation Method
Steve Turner, CEO of Protea, said: “We are pleased to have our technology recognised by the US patent office. Patents are the key assets of biotechnology, as they
Steve Turner, CEO of Protea, said: “We are pleased to have our technology recognised by the US patent office. Patents are the key assets of biotechnology, as they
The launch represents the commercialisation of a blood-based test for the detection of cancer in companion animals. The test detects the presence of Recaf, a universal marker for
The pivotal phase III clinical trial was a multi-center, world-wide, randomized, double-blind, parallel group, dose-ranging study, to assess the safety and efficacy of taliglucerase alfa in 31 treatment-naive
Previously, Javelin had reported that the top line results for its primary endpoint were not significant. The previously disclosed top line results, based upon data captured by an
Transgene has employed a novel gene silencing (within RNAi platform) technology to develop this drug. The technology involves highly selective knock-down of specific liver cancer producing gene targets,
This approval represents the final national regulatory step in taking the ReN001 therapy into patients in the UK, following regulatory approval from the UK Medicines and Healthcare Products
Daiichi Sankyo and Ranbaxy Mexico have agreed to commercialize olmesartan medoxomil, an antihypertensive discovered by Daiichi Sankyo, in Mexico. Additionally, the companies have agreed to promote prasugrel, an
The performance of the novel biomarker, AGR2, will be further tested in an up-coming multi-centre, multi-national biomarker study planned by HealthLinx. Based on preliminary data, it is expected
The company expects to complete dosing in Q3, 2010, in preparation for filing a New Drug Application (NDA) with the FDA in Q4, 2010. In 2009, an open-label
The company will move all syrup-based product manufacturing to this facility. The facility marks Elder’s entry into injectables manufacturing, especially anti-infective products like cephalosporins. The new plant involved